Tag Archives: Biosimilars Forum

August, 2017

4 August
Biosimilars Forum Applauds Senator Passage of the FDA Reauthorization Act

Washington, D.C. (August 3, 2017) – Today, the Biosimilars Forum issued the following statement on passage of the Food and Drug Administration Reauthorization Act (FDARA): “The Biosimilars Forum applauds Senate passage of the FDA Reauthorization Act. This legislation provides the agency with the resources it needs to effectively and efficiently …
Share

13 January
Biosimilars Forum Statement Regarding FDA’s Final Guidance on Nonproprietary Naming of Biosimilars

Washington, DC, January 12, 2017 – The Biosimilars Forum – the nonprofit organization solely dedicated to expanding patient access to biosimilars in the United States today issued the following statement regarding the Food and Drug Administration’s (FDA) final guidance for industry on nonproprietary naming of biological products. “The Biosimilars Forum appreciates …
Share

4 February
Biosimilars Forum Issues Statement Regarding House Energy & Commerce, Subcommittee on Health Biosimilars Hearing, Launch of New Biosimilars

Washington, DC, February 4, 2016 – The Biosimilars Forum – the nonprofit organization solely dedicated to expanding patient access to biosimilars in the United States – issued the following statement about the Biosimilars hearing before the House Energy and Commerce, Subcommittee on Health and the launch of a new biosimilars education …
Share

8 October
Biosimilars Forum Applauds Senators Roberts, Carper for Leadership on Proposed Medicare Rule on Biosimilar Coding

Washington, D.C. (October 8, 2015) – The Biosimilars Forum today expressed support for Senators Pat Roberts (R-KS) and Tom Carper (D-DE) as well as 18 additional Senators for their leadership in sending a letter to Andrew Slavitt, Acting Administrator for the Centers for Medicare & Medicaid Services (CMS) regarding the …
Share

7 May
First Nonprofit Organization Formed Dedicated to Biosimilars

A group of leading companies involved in the development of biopharmaceuticals and biosimilars have formed the first nonprofit organization dedicated to expanding patient access to biosimilars in the US. A coalition of eleven leading companies involved in developing and manufacturing biopharmaceuticals and biosimilar drugs announced the formation of the Biosimilars …
Share